Skip to content

From bench to patient: collaborating on drug development

At the Therapeutic Development Workshop, experts shared perspectives on the challenges of moving a therapy from basic research discovery to the clinic - exploring all stages of therapeutic development.

Led by UNSW Medicine and funded by the Cancer Theme and (Maridulu Budyari Gumal [SPHERE] Cancer CAG), the workshop enabled experts across all steps of drug development and the SPHERE partnership to explore ideas around commercialising research into treatments, therapies or drugs to improve health across the community.

Leader of the Translational Cancer Metabolism Laboratory in the Adult Cancer Program at UNSW, A/Prof Jeff Holst explained, “The take home message reiterated by many speakers was that we need to fail fast by doing the right commercial grade assays early in our drug development pipeline. This will save time and money and ensure we develop the best drug candidate.”

A video of the entire workshop is available here, including a handy shortcut table to take you to the speaker or section you want to view.

News about the workshop can be accessed here

First 2000 Days Care Connect - Grant Success for ELDoH CAG

Congratulations to Maridulu Budyari Gumal Early Life Determinants of Health Clinical Academic Group ((ELDoH CAG) members Ms Tania Rimes and Associate Professor Sue Woolfenden (Chief Investigators) who were awarded $840,547 through the Translational Research Grants Scheme by the New South Wales Health for their project entitled 'First 2000 Days Care Connect'.

Early/mid-career cancer researchers awarded Cancer Clinical Academic Group seed grants

Maridulu Budyari Gumal (SPHERE) Cancer Clinical Academic Group has committed $100,000 in new seed grants for two interdisciplinary projects led by early/mid-career researchers (EMCRs) to be undertaken in 2021.

Congratulations to the successful awardees and their teams.

New liquid biopsies could provide hope for brain cancer patients

Increasing the efficacy of brain cancer treatment traditionally requires access to tissue samples that can shed light on a tumour’s genetic makeup. But, with many malignancies buried deep inside essential areas of the brain, this tissue is often impossible to reach.

A new research project led by Associate Professor Therese Becker of the Ingham Institute is aiming to solve this problem. Using ‘liquid biopsies’ – that is, blood tests – the researchers hope to reveal critical information about individual patient tumours.